Article Sidebar
Date Published:
29/04/2024
Online Published:
29/04/2024
Abstract Views: 250
Views article details: 145
Views article details: 145
Issue
Section
Articles
How to Cite
Nguyen, N. T. (2024). Overview of treatments for hormonal alopecia. Journal of Disaster Medicine and Burn Injuries, 2, 69-90. https://doi.org/10.54804/yhthvb.2.2024.315
Overview of treatments for hormonal alopecia
Main Article Content
Abstract
Androgenetic alopecia (AGA) is the most common form of hair loss, which can affect an individual's quality of life. Although many medical, surgical, light therapy, and nutritional treatment options are available to slow or reverse the progression of AGA, choosing the appropriate therapy remains a challenge. This article reviews treatment options for AGA taking into account effectiveness, side effects, practicality of treatment compliance, and costs to help physicians design appropriate treatment regimens (including ethically) for patients.
Article Details
Keywords
Androgenetic alopecia, ethics, review, therapies, treatments
References
Mark S. Nestor, Glynis Ablon, Anita Gade, Haowei Han, and Daniel L. Fischer, treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics; J Cosmet Dermatol. 2021 dec; 20(12): 3759-3781
2. York K, Meah N, Bhoyrul B, Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603‐612.
3. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta‐analysis. J Am Acad Dermatol. 2017;77(1):136‐141.e5.
4. Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open‐label and global photographic assessment. Dermatol Ther. 2020;10(6):1345‐1357
5. Rundegren J. A one‐year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients. J Am Acad Dermatol. 2004;50(3):P91.
6. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo‐controlled, double‐blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767‐774.
7. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777‐2786
8. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19‐27.
9. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128‐134.
10. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27‐32.
11.Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5‐alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56‐62.
12. Pereira AFJR, Coelho TOdA. Post‐finasteride syndrome. An Bras Dermatol. 2020;95(3):271‐277.
13. Home ‐ welcome to the post‐finasteride foundation ‐ the post‐finasteride syndrome foundation. Published December 19, 2016. https://www.pfsfoundation.org/. Accessed February 24, 2021.
14. Herz‐Ruelas ME, Álvarez‐Villalobos NA, Millán‐Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338‐345.
15. Saceda‐Corralo D, Rodrigues‐Barata AR, Vañó‐Galván S, Jaén‐Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143‐145.
16. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low‐dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104‐109.
17. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2020;84(3):737‐746.
18. Vañó‐Galván S, Pirmez R, Hermosa‐Gelbard A, et al. Safety of low‐dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644‐1651.
19. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541‐556
20. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45(4):469‐475.
21. Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020;83(5):1478‐1479
22. Coneac A, Muresan A, Orasan MS. Antiandrogenic therapy with ciproterone acetate in female patients who suffer from both androgenetic alopecia and acne vulgaris. Clujul Med. 2014;87(4):226‐234
23. Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low‐level laser therapy for the treatment of androgenic alopecia: a review. Lasers Med Sci. 2018;33(2):425‐434
24. RED light treatment for hair loss ‐ the science behind REVIAN RED. Published December 21, 2019. https://revian.com/about‐revian‐red/. Accessed March 8, 2021.
25. Esmat SM, Hegazy RA, Gawdat HI, et al. Low level light‐minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med. 2017;49(9):835‐843.
26. Hesseler MJ, Shyam N. Platelet‐rich plasma and its utilities in alopecia: a systematic review. Dermatol Surg. 2020;46(1):93‐102.
27. Hausauer AK, Jones DH. Evaluating the efficacy of different platelet‐rich plasma regimens for management of androgenetic alopecia: a single‐center, blinded, randomized clinical trial. Dermatol Surg. 2018;44(9):1191‐1200
28. Kwack MH, Seo CH, Gangadaran P, et al. Exosomes derived from human dermal papilla cells promote hair growth in cultured human hair follicles and augment the hair‐inductive capacity of cultured dermal papilla spheres. Exp Dermatol. 2019;28(7):854‐857.
29. Zhou L, Wang H, Jing J, Yu L, Wu X, Lu Z. Regulation of hair follicle development by exosomes derived from dermal papilla cells. Biochem Biophys Res Commun. 2018;500(2):325‐332.
30. Ocampo‐Garza SS, Fabbrocini G, Ocampo‐Candiani J, Cinelli E, Villani A. Micro needling: a novel therapeutic approach for androgenetic alopecia, a review of literature. Dermatol Ther. 2020;33(6):e14267.
31. Neerja P. A study on the efficacy of microneedling with minoxidil solution versus microneedling with hair multivitamin solution for the treatment of androgenetic alopecia. Int J Dermatol Clin Res. 2020;6(1):10‐12.
32. Parajuli S, Paudel U. Microneedling for androgenetic alopecia not responding to conventional treatment. Our Dermatol Online. 2020;11(2):140‐142.
33. Jha AK, Vinay K, Zeeshan M, Roy PK, Chaudhary RKP, Priya A. Platelet‐rich plasma and microneedling improves hair growth in patients ofandrogenetic alopecia when used as an adjuvant to minoxidil. J Cosmet Dermatol. 2019;18(5):1330‐1335.
34. Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Microneedling in androgenetic alopecia; comparing two different depths of microneedles. J Cosmet Dermatol. 2021;20(4):1241‐1247
35. Ablon G, Kogan S. A randomized, double‐blind, placebo‐controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55‐61.
36. Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair. https://clinicaltrials.gov/ct2/show/NCT02302053. Accessed April 26, 2021.
37. Kalwat JI. The use of serenoa repens (Saw Palmetto) in hair care products. Biomed J Sci Tech Res. 2019;13(1):9725-9728.
38. Ezekwe N, King M, Hollinger JC. The use of natural ingredients in the treatment of alopecias with an emphasis on central centrifugal cicatricial alopecia: a systematic review. J Clin Aesthet Dermatol. 2020;13(8):23‐27.
39. Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202.
40. Zhou Y, Chen C, Qu Q, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta‐analysis. Dermatol Ther. 2020;33(4):e13741.
41. Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915.
42. Abdel‐Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel‐Aziz RTA. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021;34(1):e14678.
43. Alves R, Grimalt R. Platelet‐rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo‐controlled, double‐blind, half‐head study. Dermatol Surg. 2018;44(1):126‐130.
44. Inamadar A, Kumar M, Palit A. A randomized controlled, single‐observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. J Cutan Aesthet Surg. 2018;11(4):211. 10.4103/jcas.jcas_130_17
45. Chouhan K, Roga G, Kumar A, Gupta J. Approach to hair transplantation in advanced grade baldness by follicular unit extraction: a retrospective analysis of 820 cases. J Cutan Aesthet Surg. 2019;12(4):215‐222.
46. Kayiran O, Cihandide E. Evolution of hair transplantation. Plast Aesthet Res. 2018;5(3):9.
47. Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913‐914.
48. Yale K, Pourang A, Plikus MV, Mesinkovska NA. At the crossroads of 2 alopecias: androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. JAAD Case Rep. 2020;6(5):444‐446.
49. Blume‐Peytavi U, Lönnfors S, Hillmann K, Garcia BN. A randomized double‐blind placebo‐controlled pilot study to assess the efficacy of a 24‐week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794‐800.
50. Gupta AK, Bamimore MA, Foley KA. Efficacy of non‐surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta‐analyses, and an assessment of evidence quality. J Dermatolog Treat. 2020:1‐11.
51. Dhurat R, Chitallia J, May TW, et al. An open‐label randomized multicenter study assessing the noninferiority of a caffeine‐based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol. 2017;30(6):298‐305.
2. York K, Meah N, Bhoyrul B, Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603‐612.
3. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta‐analysis. J Am Acad Dermatol. 2017;77(1):136‐141.e5.
4. Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open‐label and global photographic assessment. Dermatol Ther. 2020;10(6):1345‐1357
5. Rundegren J. A one‐year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients. J Am Acad Dermatol. 2004;50(3):P91.
6. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo‐controlled, double‐blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767‐774.
7. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777‐2786
8. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19‐27.
9. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128‐134.
10. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27‐32.
11.Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5‐alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56‐62.
12. Pereira AFJR, Coelho TOdA. Post‐finasteride syndrome. An Bras Dermatol. 2020;95(3):271‐277.
13. Home ‐ welcome to the post‐finasteride foundation ‐ the post‐finasteride syndrome foundation. Published December 19, 2016. https://www.pfsfoundation.org/. Accessed February 24, 2021.
14. Herz‐Ruelas ME, Álvarez‐Villalobos NA, Millán‐Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338‐345.
15. Saceda‐Corralo D, Rodrigues‐Barata AR, Vañó‐Galván S, Jaén‐Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143‐145.
16. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low‐dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104‐109.
17. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2020;84(3):737‐746.
18. Vañó‐Galván S, Pirmez R, Hermosa‐Gelbard A, et al. Safety of low‐dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644‐1651.
19. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541‐556
20. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45(4):469‐475.
21. Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020;83(5):1478‐1479
22. Coneac A, Muresan A, Orasan MS. Antiandrogenic therapy with ciproterone acetate in female patients who suffer from both androgenetic alopecia and acne vulgaris. Clujul Med. 2014;87(4):226‐234
23. Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low‐level laser therapy for the treatment of androgenic alopecia: a review. Lasers Med Sci. 2018;33(2):425‐434
24. RED light treatment for hair loss ‐ the science behind REVIAN RED. Published December 21, 2019. https://revian.com/about‐revian‐red/. Accessed March 8, 2021.
25. Esmat SM, Hegazy RA, Gawdat HI, et al. Low level light‐minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med. 2017;49(9):835‐843.
26. Hesseler MJ, Shyam N. Platelet‐rich plasma and its utilities in alopecia: a systematic review. Dermatol Surg. 2020;46(1):93‐102.
27. Hausauer AK, Jones DH. Evaluating the efficacy of different platelet‐rich plasma regimens for management of androgenetic alopecia: a single‐center, blinded, randomized clinical trial. Dermatol Surg. 2018;44(9):1191‐1200
28. Kwack MH, Seo CH, Gangadaran P, et al. Exosomes derived from human dermal papilla cells promote hair growth in cultured human hair follicles and augment the hair‐inductive capacity of cultured dermal papilla spheres. Exp Dermatol. 2019;28(7):854‐857.
29. Zhou L, Wang H, Jing J, Yu L, Wu X, Lu Z. Regulation of hair follicle development by exosomes derived from dermal papilla cells. Biochem Biophys Res Commun. 2018;500(2):325‐332.
30. Ocampo‐Garza SS, Fabbrocini G, Ocampo‐Candiani J, Cinelli E, Villani A. Micro needling: a novel therapeutic approach for androgenetic alopecia, a review of literature. Dermatol Ther. 2020;33(6):e14267.
31. Neerja P. A study on the efficacy of microneedling with minoxidil solution versus microneedling with hair multivitamin solution for the treatment of androgenetic alopecia. Int J Dermatol Clin Res. 2020;6(1):10‐12.
32. Parajuli S, Paudel U. Microneedling for androgenetic alopecia not responding to conventional treatment. Our Dermatol Online. 2020;11(2):140‐142.
33. Jha AK, Vinay K, Zeeshan M, Roy PK, Chaudhary RKP, Priya A. Platelet‐rich plasma and microneedling improves hair growth in patients ofandrogenetic alopecia when used as an adjuvant to minoxidil. J Cosmet Dermatol. 2019;18(5):1330‐1335.
34. Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Microneedling in androgenetic alopecia; comparing two different depths of microneedles. J Cosmet Dermatol. 2021;20(4):1241‐1247
35. Ablon G, Kogan S. A randomized, double‐blind, placebo‐controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55‐61.
36. Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair. https://clinicaltrials.gov/ct2/show/NCT02302053. Accessed April 26, 2021.
37. Kalwat JI. The use of serenoa repens (Saw Palmetto) in hair care products. Biomed J Sci Tech Res. 2019;13(1):9725-9728.
38. Ezekwe N, King M, Hollinger JC. The use of natural ingredients in the treatment of alopecias with an emphasis on central centrifugal cicatricial alopecia: a systematic review. J Clin Aesthet Dermatol. 2020;13(8):23‐27.
39. Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202.
40. Zhou Y, Chen C, Qu Q, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta‐analysis. Dermatol Ther. 2020;33(4):e13741.
41. Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915.
42. Abdel‐Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel‐Aziz RTA. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021;34(1):e14678.
43. Alves R, Grimalt R. Platelet‐rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo‐controlled, double‐blind, half‐head study. Dermatol Surg. 2018;44(1):126‐130.
44. Inamadar A, Kumar M, Palit A. A randomized controlled, single‐observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. J Cutan Aesthet Surg. 2018;11(4):211. 10.4103/jcas.jcas_130_17
45. Chouhan K, Roga G, Kumar A, Gupta J. Approach to hair transplantation in advanced grade baldness by follicular unit extraction: a retrospective analysis of 820 cases. J Cutan Aesthet Surg. 2019;12(4):215‐222.
46. Kayiran O, Cihandide E. Evolution of hair transplantation. Plast Aesthet Res. 2018;5(3):9.
47. Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913‐914.
48. Yale K, Pourang A, Plikus MV, Mesinkovska NA. At the crossroads of 2 alopecias: androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. JAAD Case Rep. 2020;6(5):444‐446.
49. Blume‐Peytavi U, Lönnfors S, Hillmann K, Garcia BN. A randomized double‐blind placebo‐controlled pilot study to assess the efficacy of a 24‐week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794‐800.
50. Gupta AK, Bamimore MA, Foley KA. Efficacy of non‐surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta‐analyses, and an assessment of evidence quality. J Dermatolog Treat. 2020:1‐11.
51. Dhurat R, Chitallia J, May TW, et al. An open‐label randomized multicenter study assessing the noninferiority of a caffeine‐based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol. 2017;30(6):298‐305.